MeiraGTx Awarded Target ALS Grant For Its NMD-Based Therapy for ALS
http://www.worldpharmatoday.com/Press-Releases/meiragtx-awarded-target-als-grant-for-its-nmd-based-therapy-for-als | February 20, 2017
MeiraGTx, a New York and UK based gene therapy company, announced that it has been awarded a grant from Target ALS, a privately funded foundation bringing together a consortia of academic and biotech/pharmaceutical researchers focused on finding treatments for ALS patients.